NEWS | BEAM Alliance


Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulation and evaluates further product improvement options

Allschwil, Switzerland, July 17, 2019

Polyphor today announced that it has decided to close the Phase III PRISM MDR and UDR studies of murapavadin intravenous (i.v.) for hospital-acquired and ventilator-associated bacte-rial pneumonia (HABP/VABP) which have been put on a voluntary temporary hold on May 9th, 2019.

Full PR available here